soul trial oral semaglutide cardiovascular outcomes SELECT Effects of oral semaglutide on

doi: 10.1016/j.cbpa.2006.11.035

Quick Answer: Headache is a recognised side effect of GLP-1 receptor agonists, classified as common (1 in 10 to 1 in 100 people) for diabetes formulations and very common (more than 1 in 10) for weight-management doses

The pharmacology and neurotoxicology of synthetic cathinones

Obesity medications linked to reduced chance of MS in real world Study suggests potential for repurposing diabetes, weight-loss drugs for MS Written by | The use of obesity medications approved drugs for treating diabetes and promoting weight loss is associated with a reduced chance of developing multiple sclerosis (MS), according to real-world data from the U.S